Bilgrami, Zaid
Abutaleb, Ameer
Chudy-Onwugaje, Kenechukwu
Langenberg, Patricia
Regueiro, Miguel
Schwartz, David A.
Tracy, J. Kathleen
Ghazi, Leyla
Patil, Seema A.
Quezada, Sandra M.
Russman, Katharine M.
Quinn, Charlene C.
Jambaulikar, Guruprasad
Beaulieu, Dawn B.
Horst, Sara
Cross, Raymond K. Jr.
Funding for this research was provided by:
Agency for Healthcare Research and Quality (1R01HS018975-01A1)
University of Maryland School of Medicine Office of Student Research
Article History
Received: 23 October 2018
Accepted: 12 December 2018
First Online: 2 January 2019
Change Date: 2 December 2019
Change Type: Correction
Change Date: 2 December 2019
Change Type: Correction
Change Details: This manuscript is a secondary analysis of a large multicenter randomized controlled trial. The primary study is Cross RK et al., A Randomized Controlled Trial of TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol, 2019 Mar.
Change Details: This manuscript is a secondary analysis of a large multicenter randomized controlled trial. The primary study is Cross RK et al., A Randomized Controlled Trial of TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol, 2019 Mar.
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.